CERo Therapeutics Completes DLT Observation for Cohort 1, Doses First Patient in Cohort 2
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 17 2025
0mins
Source: Globenewswire
- Clinical Trial Progress: CERo Therapeutics has completed the dose-limiting toxicity (DLT) observation period for the first cohort in its CertainT-1 trial focused on acute myeloid leukemia, marking a significant milestone in the clinical study.
- Dose Escalation: The first patient in the second cohort received a dose of 4e6 cells/kg of CER-1236, which is four times higher than the 1e6 cells/kg administered to the first cohort, indicating the potential for enhanced therapeutic efficacy.
- Ongoing Safety Monitoring: An additional dose was provided to the second patient in the first cohort, who remains on study, demonstrating the company's commitment to safety monitoring to ensure patient well-being.
- Future Outlook: The CEO of CERo emphasized the focus on careful execution of the dose-escalation phase and systematic collection of safety data, laying the groundwork for subsequent clinical trials.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
